Cargando…
The Diagnostic Utility of Anti-cyclic Citrullinated Peptide Antibodies, Matrix Metalloproteinase-3, Rheumatoid Factor, Erythrocyte Sedimentation Rate, and C-reactive Protein in Patients with Erosive and Non-erosive Rheumatoid Arthritis
Objective: To compare the diagnostic utility of laboratory variables, including matrix metalloproteinase-3 (MMP-3), anti-cyclic citrullinated peptide (CCP) antibodies, rheumatoid factor (RF), erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP) in patients with erosive and non-erosive...
Autores principales: | , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2005
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2275423/ https://www.ncbi.nlm.nih.gov/pubmed/16295525 http://dx.doi.org/10.1080/17402520500233510 |
_version_ | 1782151869499441152 |
---|---|
author | Shovman, O. Gilburd, B. Zandman-Goddard, G. Sherer, Y. Orbach, H. Gerli, R. Shoenfeld, Y. |
author_facet | Shovman, O. Gilburd, B. Zandman-Goddard, G. Sherer, Y. Orbach, H. Gerli, R. Shoenfeld, Y. |
author_sort | Shovman, O. |
collection | PubMed |
description | Objective: To compare the diagnostic utility of laboratory variables, including matrix metalloproteinase-3 (MMP-3), anti-cyclic citrullinated peptide (CCP) antibodies, rheumatoid factor (RF), erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP) in patients with erosive and non-erosive rheumatoid arthritis (RA). Methods: We assembled a training set, consisting of 60 patients with RA, all fulfilling the revised criteria of the American College of Rheumatology. A commercial enzyme linked immunosorbent assay (ELISA) was used both to test for anti-CCP antibodies (second generation ELISA kit) and MMP; RF were detected by latex-enhanced immunonephelometric assay. CRP was measured by latex turbidimetric immunoassay. Results: The levels of anti-CCP antibody titers and ESR were significantly higher in patients with erosive disease than those in non-erosive RA patients (p < 0.001 and 0.0341) respectively. Moreover, a higher frequency of elevated titers of anti-CCP antibodies was found in RA patients with erosions compared to patients with non-erosive RA (78.3% vs. 43.2% respectively). The ROC curves of anti-CCP passed closer to the upper left corner than those other markers and area under the curve (AUC) of anti-CCP was significantly larger than AUC of other markers (0.755 for anti-CCP, 0.660 for ESR, 0.611 for CRP, 0.577 for RF, and 0.484 for MMP-3 female). A positive predictive value was higher for anti-CCP antibodies in comparison to other markers. We did not find significant statistical correlation between anti-CCP antibody titers and inflammatory markers such as ESR or CRP. However, we confirmed the correlation of elevated titers of anti-CCP antibodies and RF in both groups of patients whereas the degree of correlation was more significant in non-erosive patients. Conclusion: The results of our study suggest that the presence of elevated anti-CCP antibody titers have better diagnostic performance than MMP-3, RF, CRP and ESR in patients with erosive RA. |
format | Text |
id | pubmed-2275423 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2005 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-22754232008-03-31 The Diagnostic Utility of Anti-cyclic Citrullinated Peptide Antibodies, Matrix Metalloproteinase-3, Rheumatoid Factor, Erythrocyte Sedimentation Rate, and C-reactive Protein in Patients with Erosive and Non-erosive Rheumatoid Arthritis Shovman, O. Gilburd, B. Zandman-Goddard, G. Sherer, Y. Orbach, H. Gerli, R. Shoenfeld, Y. Clin Dev Immunol Research Article Objective: To compare the diagnostic utility of laboratory variables, including matrix metalloproteinase-3 (MMP-3), anti-cyclic citrullinated peptide (CCP) antibodies, rheumatoid factor (RF), erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP) in patients with erosive and non-erosive rheumatoid arthritis (RA). Methods: We assembled a training set, consisting of 60 patients with RA, all fulfilling the revised criteria of the American College of Rheumatology. A commercial enzyme linked immunosorbent assay (ELISA) was used both to test for anti-CCP antibodies (second generation ELISA kit) and MMP; RF were detected by latex-enhanced immunonephelometric assay. CRP was measured by latex turbidimetric immunoassay. Results: The levels of anti-CCP antibody titers and ESR were significantly higher in patients with erosive disease than those in non-erosive RA patients (p < 0.001 and 0.0341) respectively. Moreover, a higher frequency of elevated titers of anti-CCP antibodies was found in RA patients with erosions compared to patients with non-erosive RA (78.3% vs. 43.2% respectively). The ROC curves of anti-CCP passed closer to the upper left corner than those other markers and area under the curve (AUC) of anti-CCP was significantly larger than AUC of other markers (0.755 for anti-CCP, 0.660 for ESR, 0.611 for CRP, 0.577 for RF, and 0.484 for MMP-3 female). A positive predictive value was higher for anti-CCP antibodies in comparison to other markers. We did not find significant statistical correlation between anti-CCP antibody titers and inflammatory markers such as ESR or CRP. However, we confirmed the correlation of elevated titers of anti-CCP antibodies and RF in both groups of patients whereas the degree of correlation was more significant in non-erosive patients. Conclusion: The results of our study suggest that the presence of elevated anti-CCP antibody titers have better diagnostic performance than MMP-3, RF, CRP and ESR in patients with erosive RA. Hindawi Publishing Corporation 2005-09 /pmc/articles/PMC2275423/ /pubmed/16295525 http://dx.doi.org/10.1080/17402520500233510 Text en Copyright © 2005 Hindawi Publishing Corporation. http://creativecommons.org/licenses/by/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Shovman, O. Gilburd, B. Zandman-Goddard, G. Sherer, Y. Orbach, H. Gerli, R. Shoenfeld, Y. The Diagnostic Utility of Anti-cyclic Citrullinated Peptide Antibodies, Matrix Metalloproteinase-3, Rheumatoid Factor, Erythrocyte Sedimentation Rate, and C-reactive Protein in Patients with Erosive and Non-erosive Rheumatoid Arthritis |
title | The Diagnostic Utility of Anti-cyclic Citrullinated Peptide Antibodies, Matrix Metalloproteinase-3, Rheumatoid Factor, Erythrocyte Sedimentation Rate, and C-reactive Protein in Patients with Erosive and Non-erosive Rheumatoid Arthritis |
title_full | The Diagnostic Utility of Anti-cyclic Citrullinated Peptide Antibodies, Matrix Metalloproteinase-3, Rheumatoid Factor, Erythrocyte Sedimentation Rate, and C-reactive Protein in Patients with Erosive and Non-erosive Rheumatoid Arthritis |
title_fullStr | The Diagnostic Utility of Anti-cyclic Citrullinated Peptide Antibodies, Matrix Metalloproteinase-3, Rheumatoid Factor, Erythrocyte Sedimentation Rate, and C-reactive Protein in Patients with Erosive and Non-erosive Rheumatoid Arthritis |
title_full_unstemmed | The Diagnostic Utility of Anti-cyclic Citrullinated Peptide Antibodies, Matrix Metalloproteinase-3, Rheumatoid Factor, Erythrocyte Sedimentation Rate, and C-reactive Protein in Patients with Erosive and Non-erosive Rheumatoid Arthritis |
title_short | The Diagnostic Utility of Anti-cyclic Citrullinated Peptide Antibodies, Matrix Metalloproteinase-3, Rheumatoid Factor, Erythrocyte Sedimentation Rate, and C-reactive Protein in Patients with Erosive and Non-erosive Rheumatoid Arthritis |
title_sort | diagnostic utility of anti-cyclic citrullinated peptide antibodies, matrix metalloproteinase-3, rheumatoid factor, erythrocyte sedimentation rate, and c-reactive protein in patients with erosive and non-erosive rheumatoid arthritis |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2275423/ https://www.ncbi.nlm.nih.gov/pubmed/16295525 http://dx.doi.org/10.1080/17402520500233510 |
work_keys_str_mv | AT shovmano thediagnosticutilityofanticycliccitrullinatedpeptideantibodiesmatrixmetalloproteinase3rheumatoidfactorerythrocytesedimentationrateandcreactiveproteininpatientswitherosiveandnonerosiverheumatoidarthritis AT gilburdb thediagnosticutilityofanticycliccitrullinatedpeptideantibodiesmatrixmetalloproteinase3rheumatoidfactorerythrocytesedimentationrateandcreactiveproteininpatientswitherosiveandnonerosiverheumatoidarthritis AT zandmangoddardg thediagnosticutilityofanticycliccitrullinatedpeptideantibodiesmatrixmetalloproteinase3rheumatoidfactorerythrocytesedimentationrateandcreactiveproteininpatientswitherosiveandnonerosiverheumatoidarthritis AT sherery thediagnosticutilityofanticycliccitrullinatedpeptideantibodiesmatrixmetalloproteinase3rheumatoidfactorerythrocytesedimentationrateandcreactiveproteininpatientswitherosiveandnonerosiverheumatoidarthritis AT orbachh thediagnosticutilityofanticycliccitrullinatedpeptideantibodiesmatrixmetalloproteinase3rheumatoidfactorerythrocytesedimentationrateandcreactiveproteininpatientswitherosiveandnonerosiverheumatoidarthritis AT gerlir thediagnosticutilityofanticycliccitrullinatedpeptideantibodiesmatrixmetalloproteinase3rheumatoidfactorerythrocytesedimentationrateandcreactiveproteininpatientswitherosiveandnonerosiverheumatoidarthritis AT shoenfeldy thediagnosticutilityofanticycliccitrullinatedpeptideantibodiesmatrixmetalloproteinase3rheumatoidfactorerythrocytesedimentationrateandcreactiveproteininpatientswitherosiveandnonerosiverheumatoidarthritis AT shovmano diagnosticutilityofanticycliccitrullinatedpeptideantibodiesmatrixmetalloproteinase3rheumatoidfactorerythrocytesedimentationrateandcreactiveproteininpatientswitherosiveandnonerosiverheumatoidarthritis AT gilburdb diagnosticutilityofanticycliccitrullinatedpeptideantibodiesmatrixmetalloproteinase3rheumatoidfactorerythrocytesedimentationrateandcreactiveproteininpatientswitherosiveandnonerosiverheumatoidarthritis AT zandmangoddardg diagnosticutilityofanticycliccitrullinatedpeptideantibodiesmatrixmetalloproteinase3rheumatoidfactorerythrocytesedimentationrateandcreactiveproteininpatientswitherosiveandnonerosiverheumatoidarthritis AT sherery diagnosticutilityofanticycliccitrullinatedpeptideantibodiesmatrixmetalloproteinase3rheumatoidfactorerythrocytesedimentationrateandcreactiveproteininpatientswitherosiveandnonerosiverheumatoidarthritis AT orbachh diagnosticutilityofanticycliccitrullinatedpeptideantibodiesmatrixmetalloproteinase3rheumatoidfactorerythrocytesedimentationrateandcreactiveproteininpatientswitherosiveandnonerosiverheumatoidarthritis AT gerlir diagnosticutilityofanticycliccitrullinatedpeptideantibodiesmatrixmetalloproteinase3rheumatoidfactorerythrocytesedimentationrateandcreactiveproteininpatientswitherosiveandnonerosiverheumatoidarthritis AT shoenfeldy diagnosticutilityofanticycliccitrullinatedpeptideantibodiesmatrixmetalloproteinase3rheumatoidfactorerythrocytesedimentationrateandcreactiveproteininpatientswitherosiveandnonerosiverheumatoidarthritis |